Physician profile
Ryan Robert Croft
NPI 1588328314
$2,898.48
in general payments reported to CMS, 2019-2025
16 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $373 · 2023: $613 · 2024: $1,686 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,565 · Travel and Lodging: $961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.73 |
| Travel and Lodging | $960.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,454.03 | 2022-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals Lp | $284.64 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Beta Bionics, INC. | $209.95 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $193.16 | 2022-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $157.84 | 2023-2024 | Shingrix, Trelegy Ellipta |
| Edwards Lifesciences Corporation | $154.19 | 2023 | |
| Novo Nordisk INC | $138.03 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $135.40 | 2022 | |
| Tandem Diabetes Care, INC. | $36.78 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Tanabe Pharma America, INC. | $24.50 | 2023 | |
| Phathom Pharmaceuticals, INC. | $22.25 | 2024 | Voquezna |
| Indivior INC. | $21.39 | 2024 | Sublocade |
| Lilly USA, LLC | $20.10 | 2023 | Jardiance |
| Amgen INC. | $19.38 | 2024 | Repatha |
| Alexion Pharmaceuticals, INC. | $17.00 | 2024 | Strensiq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $9.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Croft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.